BD (NYSE: BDX) today announced that it completed enrollment in the iliac artery patient cohort in its pivotal AGILITY study.
The panels employ PCR techniques to test for numerous gastrointestinal bacterial pathogens using one stool swab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback